Carnivore Diet and Fatty Liver: Evidence and Risks

Carnivore and fatty liver is a topic attracting growing interest as more people explore meat-based diets to manage metabolic conditions. Fatty liver disease, now more precisely termed metabolic dysfunction-associated steatotic liver disease (MASLD), affects a significant proportion of UK adults and is closely linked to insulin resistance, obesity, and poor dietary habits. A carnivore diet eliminates all plant foods in favour of meat, fish, eggs, and dairy, which may reduce liver fat through carbohydrate restriction and weight loss. This article examines the evidence, the risks, and what NHS and NICE guidance recommends for managing fatty liver safely.

What is fatty liver disease and how is it diagnosed in the UK?

Fatty liver disease (MASLD) is diagnosed in the UK using risk stratification tools such as the FIB-4 index, with referral to a hepatologist when advanced fibrosis is suspected or red-flag symptoms are present.

Fatty liver disease is a condition in which excess fat accumulates within liver cells. In the UK it is most commonly classified as metabolic dysfunction-associated steatotic liver disease (MASLD), which is the updated international nomenclature for what NICE guidance NG49 still terms non-alcoholic fatty liver disease (NAFLD).^[1][2] Readers consulting NG49 directly will therefore see the older term; the clinical content is the same. The condition exists on a spectrum, ranging from simple steatosis (fat accumulation without significant inflammation) through to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and, in a minority of cases, cirrhosis or liver failure. A separate category, alcohol-related liver disease, applies when excess alcohol consumption is the primary driver.

In the UK, MASLD is strongly associated with obesity, type 2 diabetes, insulin resistance, and metabolic syndrome. Many people remain undiagnosed because the condition is often asymptomatic in its early stages, and liver enzymes (ALT and AST) can be normal even when significant steatosis is present.^[5] Diagnosis should not rely on raised liver enzymes alone.

The UK primary-care pathway, as described in NICE NG49 and supported by BSG and BASL guidance, typically involves initial risk stratification using a non-invasive scoring tool such as the FIB-4 index or the NAFLD Fibrosis Score, which combine routine blood results and clinical variables to estimate the likelihood of significant fibrosis. Where the result is indeterminate or suggests higher risk, enhanced liver fibrosis (ELF) testing may be arranged. Ultrasound can detect hepatic steatosis but does not reliably stage fibrosis.^[1][5] FibroScan (transient elastography) or MRI may be used for more precise assessment. Liver biopsy is reserved for selected cases where non-invasive tests are inconclusive.

A GP is usually the first point of contact. Referral to a hepatologist or gastroenterologist is considered when non-invasive testing suggests advanced fibrosis, when there is diagnostic uncertainty, or when red-flag features are present. Red flags warranting urgent assessment include jaundice accompanied by systemic illness, confusion or drowsiness suggesting encephalopathy, vomiting blood or passing black stools, rapidly progressive abdominal swelling, or fever with right upper abdominal pain. If any of these occur, seek same-day medical attention or call 999 or go to A&E as appropriate. Early identification of MASLD is important because lifestyle intervention at the steatosis stage can reverse fat accumulation before irreversible scarring develops.

Can a carnivore diet help reduce fat in the liver?

A carnivore diet may reduce liver fat by restricting carbohydrates and lowering insulin levels, but no direct clinical trials exist in MASLD patients and a GP or dietitian should be consulted before starting.

A carnivore diet, which consists almost exclusively of animal-derived foods such as meat, fish, eggs, and dairy while eliminating all plant-based foods, may reduce liver fat in some individuals. The most plausible mechanism is carbohydrate restriction and associated weight loss rather than any specific property of animal foods themselves. Hepatic fat accumulation is closely linked to excess caloric intake, insulin resistance, and high consumption of refined carbohydrates and fructose. By eliminating these, a carnivore diet can lower insulin levels and shift the body towards fat oxidation, which may reduce de novo lipogenesis (the liver's production of fat from carbohydrates).

It is important to distinguish between the mechanism and the diet. The liver-fat-reducing effects seen with very low-carbohydrate diets, including ketogenic approaches, appear to be driven largely by carbohydrate restriction and caloric deficit. Several controlled studies and systematic reviews of ketogenic and low-carbohydrate diets have demonstrated reductions in hepatic steatosis over periods of weeks to months. Direct clinical trial data on a carnivore diet specifically in people with MASLD are not currently available, so any inference about benefit is extrapolated from this related but not identical evidence base.

People with type 2 diabetes who are taking insulin or a sulfonylurea (such as gliclazide or glibenclamide) should seek a medication review from their GP or diabetes team before starting a very low-carbohydrate diet. Carbohydrate restriction can substantially lower blood glucose, increasing the risk of hypoglycaemia if insulin or sulfonylurea doses are not adjusted accordingly.

A carnivore diet is a highly restrictive eating pattern. It is not appropriate during pregnancy or breastfeeding, and is not recommended for adolescents or for individuals with a current or past history of an eating disorder, without specialist dietetic and medical supervision. For anyone considering dietary changes to manage fatty liver, a consultation with a GP or registered dietitian is strongly recommended before making significant dietary shifts. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support; this may be relevant for those whose fatty liver is linked to obesity or metabolic conditions, and any medicine would only be prescribed where clinically appropriate following a consultation. Any dietary approach should be tailored to the individual's full clinical picture, including existing conditions such as diabetes or kidney disease.

What does the evidence say about high-fat, meat-based diets and liver health?

Short-term studies show ketogenic and low-carbohydrate diets can reduce hepatic fat, but carnivore-specific evidence is absent and long-term effects of very high saturated fat intake on liver health remain uncertain.

The evidence on high-fat, meat-based diets and liver health is mixed and context-dependent, and no large randomised controlled trials have specifically examined the carnivore diet in people with MASLD. Most available evidence comes from studies on ketogenic diets, very low-calorie diets, and low-carbohydrate high-fat diets, which share some characteristics with a carnivore approach but are not identical.

Several short-term controlled studies have shown that ketogenic and very low-carbohydrate diets can significantly reduce hepatic fat content, improve liver enzyme levels, and reduce markers of insulin resistance within weeks. A study published in Cell Metabolism in 2020 (Luukkonen et al.) demonstrated that a ketogenic diet reduced liver fat and improved metabolic markers in people with NAFLD over a 12-week period. Systematic reviews and meta-analyses of low-carbohydrate dietary interventions in NAFLD have broadly supported short-term reductions in hepatic steatosis, though longer-term data are limited. These findings suggest that carbohydrate restriction, which is a feature of the carnivore diet, may be beneficial for liver fat reduction in the short term, but direct carnivore-specific evidence is lacking.

Conversely, concerns exist about the long-term effects of very high saturated fat intake on liver health. Animal studies have shown that diets very high in saturated fat can promote hepatic inflammation and fibrosis. Human evidence on this question is less clear-cut: the source and type of dietary fat, overall caloric balance, and individual metabolic factors all influence outcomes, and dose-response relationships in humans are not well established. Extrapolating directly from animal data to human clinical practice requires caution.

In observational research, higher consumption of processed red meat and high dietary sodium have been associated with adverse metabolic outcomes, though these are observational associations subject to confounding and do not establish causality. By contrast, Mediterranean-style dietary patterns, which emphasise vegetables, legumes, wholegrains, fish, and olive oil, have the strongest evidence base for liver benefit in MASLD and are frequently highlighted by hepatology teams in clinical practice.

The overall evidence base remains insufficient to make firm recommendations for or against a carnivore diet specifically for liver health.

Are there risks of making fatty liver worse on a carnivore diet?

A carnivore diet high in saturated fat may worsen hepatic inflammation in those with existing MASH, and rapid weight loss increases the risk of gallstones and can temporarily worsen liver inflammation.

A carnivore diet carries several potential risks that could, in certain circumstances, worsen liver health rather than improve it, and these deserve careful consideration before adoption.

The most significant concern relates to diet composition. A carnivore diet that is very high in saturated fat, particularly from processed meats such as bacon, sausages, and cured products, may promote hepatic inflammation in individuals who already have MASH or significant fibrosis. Some human studies suggest that high saturated fat intake is associated with markers of hepatic inflammation, though the evidence is not conclusive and the degree of risk depends on overall caloric balance and individual metabolic factors.

Rapid weight loss can also be a concern. Losing weight very quickly, as can occur with highly restrictive diets, carries a recognised risk of worsening liver inflammation in susceptible individuals, a phenomenon documented in the context of very low-calorie diets and following bariatric surgery. Rapid weight loss also substantially increases the risk of gallstone formation, which can cause biliary colic or cholecystitis.^[6] If you develop upper abdominal pain, particularly after eating fatty foods, or notice yellowing of the skin or eyes, contact your GP promptly.

The complete elimination of dietary fibre on a carnivore diet alters the gut microbiome. Emerging evidence suggests that gut microbiome composition plays a role in MASLD progression, and a fibre-free diet may reduce the production of short-chain fatty acids that support gut barrier integrity and reduce hepatic inflammation, though this area of research is still developing and firm conclusions cannot yet be drawn.

People with existing liver conditions, including those with type 2 diabetes or advanced fibrosis, should discuss any major dietary change with their GP or hepatologist before proceeding. If you experience new or worsening symptoms such as persistent fatigue, abdominal discomfort, or jaundice, contact your GP promptly.

What do NHS and NICE guidelines recommend for fatty liver management?

NICE NG49 recommends lifestyle modification and 7 to 10 per cent weight loss for MASLD; Mediterranean-style diets have the strongest evidence and no single named diet, including carnivore, is endorsed.

NICE guidance NG49 (Non-alcoholic Fatty Liver Disease: Assessment and Management) recommends lifestyle modification as the cornerstone of MASLD management, with a focus on weight loss, increased physical activity, and dietary improvement. The guidance does not endorse any single named diet, including carnivore, ketogenic, or Mediterranean approaches, but notes that a sustained reduction in body weight of 7 to 10 per cent is associated with meaningful reductions in hepatic steatosis and, in some cases, regression of fibrosis.^[1][3] NICE Quality Standard QS152 supports case-finding, risk stratification, and follow-up in primary care.

The NHS broadly recommends a balanced diet that limits saturated fat, refined sugars, and alcohol, while encouraging wholegrains, vegetables, lean protein, and healthy fats. Mediterranean-style dietary patterns have the strongest evidence for liver benefit in MASLD and are often highlighted by hepatology teams in clinical practice, though NICE does not mandate a single dietary model.

For individuals with type 2 diabetes and MASLD, NICE recommends optimising glycaemic control, as insulin resistance is a key driver of hepatic fat accumulation. Pharmacological options for MASLD are an active area of research. NICE has not licensed or recommended any medicine specifically for MASLD itself, though medicines used for associated conditions, such as GLP-1 receptor agonists used for type 2 diabetes or obesity, have shown reductions in liver fat as a secondary outcome in clinical trials; this does not constitute a licensed indication for liver disease.^[8][9]

Regarding alcohol, the UK Chief Medical Officers' low-risk drinking guidelines advise that it is safest not to drink more than 14 units per week on a regular basis, spread over three or more days, with several alcohol-free days each week.^[7] For people with established liver disease, specialist hepatology teams typically advise avoiding alcohol entirely; patients should follow the advice given by their own clinical team.

Patients should be reviewed regularly by their GP, and those with evidence of significant fibrosis or cirrhosis should be under specialist hepatology care.

How to monitor your liver health if you are following a carnivore diet

Liver health should be monitored with baseline and repeat liver function tests every three to six months, alongside lipid profiles, with GP review if ALT or AST rises or symptoms such as jaundice develop.

Monitoring liver health while following a carnivore diet involves a combination of blood tests, imaging, and awareness of symptoms, and should be conducted in partnership with a GP rather than through self-monitoring alone. Before starting any significant dietary change, it is advisable to establish a baseline by asking your GP for a liver function test (LFT), which measures enzymes including ALT, AST, and GGT, alongside a fasting lipid profile and blood glucose or HbA1c. These results provide a reference point against which future changes can be compared.

After starting a carnivore diet, repeat blood tests at three to six months are a reasonable interval to assess whether liver enzymes are improving, stable, or worsening. This reflects typical practice in primary care, though your GP may suggest a different schedule depending on your individual circumstances. A rising ALT or AST in the context of dietary change warrants prompt GP review and may indicate hepatic stress rather than benefit. Lipid profiles are particularly important to monitor on a high-fat diet, as some individuals experience significant rises in LDL cholesterol, which carries cardiovascular implications independent of liver health.

Ultrasound or FibroScan may be arranged by a GP or specialist to assess changes in liver fat and stiffness over time, particularly in those with known MASLD or risk factors for fibrosis. Availability of these investigations and the referral route depend on local Integrated Care Board (ICB) pathways and may vary across the UK. Keeping a food and symptom diary can help identify patterns and support more productive clinical conversations.

Symptoms that should prompt same-day contact with a GP or use of NHS 111 include persistent right upper abdominal discomfort, unexplained fatigue, nausea, or any yellowing of the skin or eyes (jaundice). Symptoms requiring emergency assessment (call 999 or go to A&E) include confusion or drowsiness, vomiting blood or passing black stools, and fever with severe abdominal pain. These may indicate serious liver disease and require prompt assessment. Suspected adverse effects from any medicine taken alongside a dietary change can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD) – NG49.
2. Scope for guideline update (starting 2025) – GID-NG10434.
3. Non-alcoholic fatty liver disease (NAFLD) – NG49 short version of draft guideline.
4. Alcoholic fatty liver disease [DAP59] – Final Protocol.
5. Non-alcoholic fatty liver disease (NAFLD).
6. Gallstones.
7. Alcohol consumption: advice on low risk drinking. UK Chief Medical Officers..
8. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. Newsome PN et al..
9. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis. Loomba R et al..

Frequently Asked Questions